When the associations of the selected NANOG-regulated miRNAs with clinical parameters were analysed, we found that low expression of MIR9-2 was associated with higher tumour stages and presence of GCNIS, both indicating progression to an invasive tumour phenotype. Here, NANOG is linked to neoplasm.